How This Reference Is Built
Editorial Methodology
The Park Ave clinical reference library is sourced, drafted, peer-reviewed, and maintained under a documented editorial process. This page describes that process in full.
Source identification
Primary peer-reviewed literature is identified through PubMed, Google Scholar, and ClinicalTrials.gov. Preference is given to randomized controlled trials, meta-analyses, mechanism studies in peer-reviewed journals, and FDA / EMA documentation where applicable. Industry whitepapers are used only for analytical and handling references, never for clinical claims.
Drafting
Each entry is drafted by a research writer with a scientific background using only the source set above. Drafts follow a fixed structure: field of medicine, background, mechanism of action, molecular profile, pharmacokinetics, research applications, storage and handling, FAQ, and selected references.
Peer review
Drafts are reviewed by a member of the Clinical Review Board with subject-matter expertise in the relevant field. The reviewer verifies mechanism, pharmacokinetics, and research applications against the primary literature.
Quality and documentation review
Quality Assurance verifies molecular profile data (formula, weight, sequence, CAS), purity standards, and storage guidance against current analytical references and our internal lot-release documentation.
Publication and revision
Entries are published with a "last reviewed" date. Each entry is re-reviewed at minimum annually, and immediately when a peer-reviewed publication materially changes the mechanism or research context.
Conflicts of interest
Editorial review is independent of commercial decisions. Reviewers disclose any relationships with manufacturers, study sponsors, or regulatory bodies, and recuse themselves from entries where a material conflict exists.
Corrections
If you identify an inaccuracy in any entry, contact the editorial team. Corrections are reviewed and published within five business days, with a dated correction note.